Evidence for COL1A2 aberrant promoter methylation has been described in different cancer cells such as breast cancer, medulloblastoma, hepatoma, colorectal cancer [26], [27], [28] and more recently in melanoma [12], [21]. This evidence concerns the gene COL1A2 and breast carcinoma.